About Octagon Therapeutics
Octagon Therapeutics is a private company based in Providence, Rhode Island. It has reported $12,416,723 raised in four offerings on Form D since October 2018.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jan 29, 2024 | Feb 12, 2024 | $10,970,135of $12.4M target | 53 | $206K | Equity, OptionsRule 506(b) | Form D ↗ |
| Jun 1, 2020 | Jun 10, 2020 | $398,000of $1.0M target | 8 | $49,750 | Securities on exercise, Convertible DebtRule 506(b) | Form D ↗ |
| Nov 15, 2019 | Nov 26, 2019 | $511,000fully sold | 10 | $51,100 | Debt, OptionsRule 506(b) | Form D ↗ |
| Oct 15, 2018 | Oct 25, 2018 | $537,588of $1.0M target | 2 | $268K | Debt, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, four offerings | $12,416,723 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Octagon Therapeutics's Form D filed Feb 12, 2024.
Earlier filings also listed Fred Ausubel (executive officer and director, last listed Jun 2020), Paul Goldenheim (director, last listed Nov 2019) and Shen Yu (executive officer and director, last listed Oct 2018).